Furthermore, the study highlighted the importance to analyze LYN/HS1 axis in CLL patients; in fact, dasatinib variable results in clinical trials80 may depend on LYN/HS1 activation status.79 Many clinical trials on dasatinib treatment in CLL are currently ongoing or have been completed (clinicaltrials.gov). This evidence concerns the gene LYN and B-cell chronic lymphocytic leukemia.